Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans

IL Williams, PJ Chowienczyk, SB Wheatcroft, AG Patel, RA Sherwood, AM Shah, MT Kearney

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Endothelial dysfunction is a pivotal early event in the development of atherosclerosis and a characteristic feature of obesity. This study was designed to investigate the effect of angiotensin-converting enzyme (ACE) inhibition on endothelial function in people who were obese but otherwise healthy. We performed a double-blind, randomised, placebo-controlled study examining the effect of the ACE inhibitor perindopril (4 mg per day) on flow-mediated vasodilatation (FMD) of the brachial artery, arterial blood pressure, glucose homeostasis and inflammatory cytokines. Eighteen obese subjects (all body mass index > 30 kg/m2) were randomised to receive perindopril or placebo for four weeks. Perindopril led to a fall in systolic blood pressure from 131 (standard error of mean [SEM] 3) to 117(5) mmHg and diastolic blood pressure from 74(4) mmHg to 68(4) mmHg, both p
Original languageEnglish
Pages (from-to)34 - 38
Number of pages5
JournalDiabetes & vascular disease research
Volume3
Issue number1
DOIs
Publication statusPublished - May 2006

Fingerprint

Dive into the research topics of 'Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans'. Together they form a unique fingerprint.

Cite this